
January to March 2022
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| AFLIBERCEPT | $125,089,443 | 105,094 |
| PEMBROLIZUMAB | $107,783,752 | 12,689 |
| NIVOLUMAB | $102,979,685 | 13,107 |
| USTEKINUMAB | $74,787,856 | 10,504 |
| ADALIMUMAB | $67,517,591 | 75,408 |
| APIXABAN | $64,780,953 | 815,701 |
| DENOSUMAB | $61,752,019 | 247,015 |
| LENALIDOMIDE | $59,891,794 | 10,916 |
| OCRELIZUMAB | $49,083,316 | 2,823 |
| RANIBIZUMAB | $48,875,839 | 42,160 |
| DUPILUMAB | $41,300,037 | 24,195 |
| RIVAROXABAN | $38,843,745 | 597,999 |
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| ROSUVASTATIN | $19,338,633 | 3,689,869 |
| ATORVASTATIN | $16,159,014 | 2,855,252 |
| PANTOPRAZOLE | $12,567,033 | 2,327,962 |
| ESOMEPRAZOLE | $16,796,446 | 1,975,132 |
| PERINDOPRIL | $8,732,467 | 1,677,155 |
| ESCITALOPRAM | $4,851,239 | 1,431,289 |
| SERTRALINE | $4,772,863 | 1,331,687 |
| METFORMIN | $7,682,862 | 1,306,839 |
| CEFALEXIN | $4,443,957 | 1,142,945 |
| AMLODIPINE | $5,010,607 | 1,098,092 |
| TELMISARTAN | $5,300,640 | 1,060,499 |
| IRBESARTAN | $5,143,154 | 980,323 |
| Contributor | Contribution Dollars |
|---|---|
| Australian Government | $3,413,934,065 |
| Patients | $903,287,339 |